No Data
No Data
Fujian Cosunter Pharmaceutical Completes Virology Phase 2 Trials for Hepatitis B Drug
Fujian Cosunter Pharmaceutical (300436.SZ): The phase II clinical study summary report of innovative drug GST-HG141 for the treatment of hepatitis B
On September 8th, Gesundheit (300436.SZ) announced that the company's hepatitis B treatment innovative drug GST-HG141 has completed the phase II clinical trial of hepatitis B low viral load (LLV), and recently obtained the research summary report of the phase II clinical trial. The research results show that GST-HG141 tablets have good safety and significant efficacy for patients with chronic hepatitis B low viral load. The inhibitory effect on HBV DNA is significantly better than the currently clinically recommended nucleos(t)ide analog monotherapy control group, further confirming its further inhibition on the basis of nucleos(t)ide analog drug treatment in hepatitis B patients.
Fujian Cosunter Pharmaceutical (300436.SZ): GST-HG141 tablets have good safety and significant efficacy for patients with chronic hepatitis B and low viral load.
Fujian Cosunter Pharmaceutical (300436.SZ) announced that the company's innovative drug GST-HG141 for the treatment of hepatitis B has completed Phase III clinical trials.
Koseido: 2024 Semi-Annual Report Summary
Koseido: 2024 Semi-Annual Report
Fujian Cosunter Pharmaceutical (300436.SZ): Net loss of 36.0378 million yuan in the first half of the year, a decrease in loss compared to the same period last year.
Fujian Cosunter Pharmaceutical (300436.SZ) announced its semi-annual report for 2024, with a total operating income of 0.218 billion yuan, a year-on-year increase of 22.93%; net income attributable to shareholders of the listed company -36.0378 million yuan, a year-on-year decrease in loss; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses -48.2001 million yuan, a year-on-year decrease in loss; basic earnings per share -0.2263 yuan.
No Data
No Data